2 results
Approved WMOPending
Primary Objective • To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) or weight in patients with T2D following 65 weeks of treatment. The non-inferiority margins…
Approved WMOPending
We aim to assess whether risk modification effectiveness is visible on follow-up CT and in biomarker values when comparing baseline with 12 months follow-up in patients without significant obstructive coronary artery disease on coronary Ct. We also…